Corcept Therapeutics Inc

CORT remains in a Stage 2 advance marked by higher highs and higher lows. After peaking at overbought levels, price has pulled back into the rising 9 and 21 EMA zone and is holding above support. EMAs are positively sloped and layered, RSI has eased from overbought into neutral territory, and volume patterns remain healthy. The speculative strategy supports a tactical pullback entry into dynamic support.

• ↑Relacorilant FDA approved ahead of schedule, projected >$1B revenue by 2030.
• ↑2026 revenue guidance raised to $950M–$1.05B after strong clinical results.
• ↓Q1 net loss $31.8M vs $20.5M profit year ago indicates loss pressure.